Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
To analyze the efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia. Sixty-six elderly hypertensive patients with hyperuricemia admitted to Beijing Civil Aviation General Hospital from February 2017 to February 2018 were enrolled in the study. According to computer randomization method, they were divided into two groups: The control group and the treatment group and there were 33 cases in each group. The routine treatment was used in the control group. The conventional treatment combined with benzbromarone treatment was applied to the treatment group. The clinical efficacy, blood pressure, blood uric acid level, inflammatory factor level and adverse event rate were analyzed. Clinical efficacy of the treatment group was higher than that of the control group (P<0.05); blood pressure, blood uric acid level, and inflammatory factor level in the treatment group was better than that of the control group (P<0.05); the incidence of adverse events in the treatment group was lower than that of the control group (P<0.05). Elderly hypertensive patients with hyperuricemia treated with benzbromarone have a significant clinical effect, which has a positive effect on improving clinical symptoms and reducing the probability of adverse events and has a high clinical promotion value.